These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 18622040

  • 1. Alpha-synuclein A30P point-mutation generates age-dependent nigrostriatal deficiency in mice.
    Plaas M, Karis A, Innos J, Rebane E, Baekelandt V, Vaarmann A, Luuk H, Vasar E, Koks S.
    J Physiol Pharmacol; 2008 Jun; 59(2):205-16. PubMed ID: 18622040
    [Abstract] [Full Text] [Related]

  • 2. Comparison of motor performance, brain biochemistry and histology of two A30P α-synuclein transgenic mouse strains.
    Piltonen M, Savolainen M, Patrikainen S, Baekelandt V, Myöhänen TT, Männistö PT.
    Neuroscience; 2013 Feb 12; 231():157-68. PubMed ID: 23219665
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein.
    Marxreiter F, Nuber S, Kandasamy M, Klucken J, Aigner R, Burgmayer R, Couillard-Despres S, Riess O, Winkler J, Winner B.
    Eur J Neurosci; 2009 Mar 12; 29(5):879-90. PubMed ID: 19291219
    [Abstract] [Full Text] [Related]

  • 6. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
    Miller RM, Kiser GL, Kaysser-Kranich T, Casaceli C, Colla E, Lee MK, Palaniappan C, Federoff HJ.
    Exp Neurol; 2007 Mar 12; 204(1):421-32. PubMed ID: 17254569
    [Abstract] [Full Text] [Related]

  • 7. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.
    Taylor TN, Potgieter D, Anwar S, Senior SL, Janezic S, Threlfell S, Ryan B, Parkkinen L, Deltheil T, Cioroch M, Livieratos A, Oliver PL, Jennings KA, Davies KE, Ansorge O, Bannerman DM, Cragg SJ, Wade-Martins R.
    Neurobiol Dis; 2014 Feb 12; 62():193-207. PubMed ID: 24121116
    [Abstract] [Full Text] [Related]

  • 8. Gene dosage and pathogenesis of Parkinson's disease.
    Eriksen JL, Przedborski S, Petrucelli L.
    Trends Mol Med; 2005 Mar 12; 11(3):91-6. PubMed ID: 15760766
    [Abstract] [Full Text] [Related]

  • 9. Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background.
    Cabin DE, Gispert-Sanchez S, Murphy D, Auburger G, Myers RR, Nussbaum RL.
    Neurobiol Aging; 2005 Jan 12; 26(1):25-35. PubMed ID: 15585343
    [Abstract] [Full Text] [Related]

  • 10. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients.
    Chiba-Falek O, Lopez GJ, Nussbaum RL.
    Mov Disord; 2006 Oct 12; 21(10):1703-8. PubMed ID: 16795004
    [Abstract] [Full Text] [Related]

  • 11. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
    Poon HF, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA.
    Neurobiol Dis; 2005 Apr 12; 18(3):492-8. PubMed ID: 15755676
    [Abstract] [Full Text] [Related]

  • 12. Dopamine receptor agonists reverse behavioral abnormalities of alpha-synuclein transgenic mouse, a new model of Parkinson's disease.
    Wakamatsu M, Iwata S, Funakoshi T, Yoshimoto M.
    J Neurosci Res; 2008 Feb 15; 86(3):640-6. PubMed ID: 17896793
    [Abstract] [Full Text] [Related]

  • 13. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
    Ono K, Ikemoto M, Kawarabayashi T, Ikeda M, Nishinakagawa T, Hosokawa M, Shoji M, Takahashi M, Nakashima M.
    Parkinsonism Relat Disord; 2009 Nov 15; 15(9):649-54. PubMed ID: 19345133
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice.
    Peneder TM, Scholze P, Berger ML, Reither H, Heinze G, Bertl J, Bauer J, Richfield EK, Hornykiewicz O, Pifl C.
    Neuroscience; 2011 Apr 28; 180():280-92. PubMed ID: 21333719
    [Abstract] [Full Text] [Related]

  • 16. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A, Rota D, Debetto P, Peroni D, Guidolin D, Negro A, Skaper SD, Giusti P.
    Neurobiol Dis; 2008 Apr 28; 30(1):8-18. PubMed ID: 18313315
    [Abstract] [Full Text] [Related]

  • 17. [Relationship between alpha-synuclein and Parkinson's disease].
    Nishioka K, Hattori N.
    Brain Nerve; 2007 Aug 28; 59(8):825-30. PubMed ID: 17713118
    [Abstract] [Full Text] [Related]

  • 18. Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.
    Freichel C, Neumann M, Ballard T, Müller V, Woolley M, Ozmen L, Borroni E, Kretzschmar HA, Haass C, Spooren W, Kahle PJ.
    Neurobiol Aging; 2007 Sep 28; 28(9):1421-35. PubMed ID: 16872721
    [Abstract] [Full Text] [Related]

  • 19. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice.
    Nieto M, Gil-Bea FJ, Dalfó E, Cuadrado M, Cabodevilla F, Sánchez B, Catena S, Sesma T, Ribé E, Ferrer I, Ramírez MJ, Gómez-Isla T.
    Neurobiol Aging; 2006 Jun 28; 27(6):848-56. PubMed ID: 16006012
    [Abstract] [Full Text] [Related]

  • 20. First appraisal of brain pathology owing to A30P mutant alpha-synuclein.
    Seidel K, Schöls L, Nuber S, Petrasch-Parwez E, Gierga K, Wszolek Z, Dickson D, Gai WP, Bornemann A, Riess O, Rami A, Den Dunnen WF, Deller T, Rüb U, Krüger R.
    Ann Neurol; 2010 May 28; 67(5):684-9. PubMed ID: 20437567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.